Why Galecto (GLTO) Shares Are Down 27% Today
Why Galecto (GLTO) Shares Are Down 27% Today
In exchange for the rights to BRM-1420, Galecto issued shares representing 4.99% of its outstanding common stock to Bridge Medicines, along with preferred shares that could convert to an additional 12.8% of common stock upon stockholder approval. Galecto Inc (NASDAQ:GLTO) shares are trading lower by 27% to $8.50 during Monday's session. The company issued 62,594 shares of common stock and 160,562 of preferred convertible shares to Bridge Medicine as part of their acquisition for the rights to BRM-1420.
Galecto公司（納斯達克股票代碼：GLTO）股價在週一交易時下跌了27%，跌至8.50美元。該公司發行了62,594股普通股和160,562股可轉換優先股給Bridge Medicine，作爲其收購BRm-1420權利的一部分。
What Happened: Galecto announced a strategic shift to focus on cancer and liver disease, particularly leveraging its clinical-stage asset GB1211, which the company says has shown positive results in non-small cell lung cancer (NSCLC) and cirrhosis studies.
事件經過：Galecto宣佈戰略轉變，專注於癌症和肝病，特別是利用其臨床階段資產GB1211，該公司表示已在非小細胞肺癌（NSCLC）和肝硬化研究中顯示出積極結果。
To strengthen its pipeline, Galecto has acquired global rights to BRM-1420, a novel drug developed by Bridge Medicines, a company co-founded by Takeda. Galecto says BRM-1420 has shown promise in treating genetic subsets of acute myeloid leukemia (AML) and could enhance standard therapies.
爲加強其產品線，Galecto已獲得了Bridge Medicines開發的新藥BRm-1420的全球權利，這是Takeda共同創立的一家公司。Galecto表示，BRm-1420在治療急性骨髓性白血病（AML）的遺傳亞組方面表現出潛力，並可能增強標準療法。
In exchange for the rights to BRM-1420, Galecto issued shares representing 4.99% of its outstanding common stock to Bridge Medicines, along with preferred shares that could convert to an additional 12.8% of common stock upon stockholder approval.
作爲對BRm-1420權利的交換，Galecto發行了代表其未來普通股4.99%的股份給Bridge Medicines，併發行可轉換爲普通股額外12.8%的優先股，需股東批准。
Matthew Kronmiller, CEO of Bridge Medicines, will join Galecto as Executive Vice President of Strategy and Chief Business Officer. The transaction was approved by both companies' boards, with Leerink Partners advising Galecto and Lazard advising Bridge Medicines.
Matthew Kronmiller，Bridge Medicines的首席執行官，將加入Galecto擔任戰略與業務首席副總裁。交易獲得了雙方董事會的批准，Leerink Partners爲Galecto提供建議，Lazard爲Bridge Medicines提供建議。
Read Also: S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
閱讀更多：標普500指數12個月內可能達到6300點，高盛表示，受到「強勁人工智能需求」和「利潤擴張」的驅動。
How To Buy GLTO Stock
如何購買GLTO股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了手動到經紀所平台購買股票或者部分股票，您還可以通過購買持有股票的ETF，或者在401(k)中分配資金進入一項該類基金或其他工具的策略來獲得股票的份額。例如，Coinbase屬於金融部門。ETF通常持有許多能跟蹤該部門的流動性和大型公司的股票，使投資者能夠獲得該股票板塊內的趨勢。
For example, in Galecto's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
舉例來說，對於galecto的情況，它屬於醫療保健板塊。一個etf可能會持有許多流通性強、規模大的公司股票，幫助跟蹤該板塊，使投資者能夠接觸到該板塊內的趨勢。
According to data from Benzinga Pro, GLTO has a 52-week high of $23.50 and a 52-week low of $8.45.
根據Benzinga Pro的數據，GLTO的52周最高價爲23.50美元，52周最低價爲8.45美元。
譯文內容由第三人軟體翻譯。
